Sunvozertinib A Next-Generation EGFR Exon 20 Insertion Inhibitor Transforming NSCLC Therapy.

Abstract

Sunvozertinib (DZD9008) is an emerging next-generation, highly selective EGFR tyrosine kinase inhibitor (TKI) designed to target EGFR exon 20 insertion (Ex20ins) mutations, a subtype of non-small cell lung cancer (NSCLC) associated with poor response to earlier-generation EGFR TKIs. Patients with these mutations typically exhibit intrinsic resistance to approved standard EGFR inhibitors due to the altered conformation of the kinase domain. Consequently, therapeutic options have remained limited, and platinum-doublet chemotherapy has historically been the primary systemic treatment. Recently developed agents such as amivantamab and mobocertinib have improved response rates, yet challenges related to tolerability, CNS penetration, and durability of benefit persist. Sunvozertinib aims to address these limitations through rational structural design, optimized kinase selectivity, and improved safety-efficacy balance. Preclinical studies have shown potent inhibition of a broad spectrum of EGFR Ex20ins variants while sparing wild-type EGFR, suggesting a reduced risk of dose-limiting toxicities commonly seen with non-selective EGFR blockade. Sunvozertinib has also demonstrated promising CNS activity in animal models-an important feature for NSCLC patients, who frequently develop brain metastases. Early-phase clinical trials, including the WU-KONG series, have reported promising clinical efficacy, including objective response rates ranging from 44-60% in previously treated patients and meaningful activity in treatment-naïve cohorts. The tolerability profile of the drug seems manageable, with diarrhea, rash, and stomatitis among the most commonly observed adverse events; these, however, tend to be milder compared with other agents targeting EGFR Ex20ins.